Clinical Trial in a Plate
Cellectricon AB and Censo Biotechnologies Ltd. are introducing a joint technology access programme for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.
The approach is based on human induced pluripotent stem cells (HiPSC) sourced and produced by Censo, combined with Cellectricon’s proprietary screening platform, IP and know-now. The joint technology access programme will enable high quality phenotypic screening of medium throughput compound libraries in customized human IPSC-derived diseased and healthy control models.
The power of HiPSC technology includes reduced risk of late stage failures by encompassing increased biological relevance and by bridging the gap between preclinical and clinical data. The HiPSC technology also makes it possible to generate isogenic control lines from disease-bearing individuals thereby creating a genetically corrected control.
A phenotypic approach directly interrogates physiologically relevant biology in a target and pathway agnostic manner, increasing the probability of finding/targeting novel mechanisms.
”Primary screening of drug candidates, hit validation, optimisation, toxicology can be efficiently followed by clinical trials in a plate testing the drug candidates in many patient lines to capture more genetic diversity and get a better sense of the robustness of the compound effects,” says Dr. Mattias Karlsson, CEO of Cellectricon, a leading provider of highly differentiated cell-based discovery services to enable faster drug discovery with reduced costs and failure rates. The company is situated in Mölndal, Sweden.
Discovery of First-in-Class Medicines
Currently, there are no ways to model sporadic disease in non-human systems that offer a way forward for diseases of the central nervous system and chronic pain. This programme, on the other hand, enables discovery of first-in-class medicines using phenotypic screening both on the cellular and network level.
“Differences in target composition and neuronal processing between humans and model organisms may lead to poor translation between animal studies and the clinical setting. By gaining access to human cells from virtually any disorder, our collaboration with Censo has significantly enhanced our discovery services offering for CNS and chronic pain research,” says Paul Karila, VP Discovery Services at Cellectricon.
“There is an excellent alignment between Censo and Cellectricon. Our extensive expertise in the production of ethically approved human iPSCs and derivatives adds further value to Cellectricon’s proprietary discovery services. We are very excited that this program will enable clients to access highly relevant screening cascades,” comments Aidan Courtney, CEO of Censo, a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. The company is based in Cambridge, UK.
”The programme provides massive cost savings for our clients by avoiding the need for capital expenditures and personnel investments in stem cell production, assay development, and screening,” says Mattias Karlsson, who also points to the benefits of reduced risk and shortened lead times in the discovery phase by up to more than two years.